Dr. Stephen E. Spurgeon
Claim this profileOHSU Knight Cancer Institute
Area of expertise
Mantle Cell Lymphoma
Stephen E. Spurgeon has run 2 trials for Mantle Cell Lymphoma. Some of their research focus areas include:
Lymphoma
Stephen E. Spurgeon has run 2 trials for Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
OHSU Knight Cancer Institute
Oregon Health And Science University
Clinical Trials Stephen E. Spurgeon is currently running
Mosunetuzumab + Chemotherapy
for Diffuse Large B-Cell Lymphoma
This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as mosunetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as etoposide, doxorubicin, vincristine, cyclophosphamide and prednisone work in different ways to stop the growth of cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mosunetuzumab with chemotherapy may be safe, tolerable and/or effective in treating patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma.
Recruiting
1 award
Phase 1 & 2
Triple Therapy
for Chronic Lymphocytic Leukemia
This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CLL and SLL are types of cancer that develops from a specific white blood cell called B cells or B lymphocytes. Tafasitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell cancers such as CLL at abnormal levels. This may help keep cancer cells from growing and spreading. Giving tafasitamab, acalabrutinib, and obinutuzumab may kill more cancer cells in patients with previously untreated CLL and SLL.
Recruiting
1 award
Phase 1
More about Stephen E. Spurgeon
Clinical Trial Related
7 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Stephen E. Spurgeon has experience with
- Obinutuzumab
- Ibrutinib
- Acalabrutinib
- Cytarabine
- Glofitamab
- Chemotherapy
Breakdown of trials Stephen E. Spurgeon has run
Mantle Cell Lymphoma
Lymphoma
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen E. Spurgeon specialize in?
Stephen E. Spurgeon focuses on Mantle Cell Lymphoma and Lymphoma. In particular, much of their work with Mantle Cell Lymphoma has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Stephen E. Spurgeon currently recruiting for clinical trials?
Yes, Stephen E. Spurgeon is currently recruiting for 2 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Stephen E. Spurgeon has studied deeply?
Yes, Stephen E. Spurgeon has studied treatments such as Obinutuzumab, Ibrutinib, Acalabrutinib.
What is the best way to schedule an appointment with Stephen E. Spurgeon?
Apply for one of the trials that Stephen E. Spurgeon is conducting.
What is the office address of Stephen E. Spurgeon?
The office of Stephen E. Spurgeon is located at: OHSU Knight Cancer Institute, Portland, Oregon 97239 United States. This is the address for their practice at the OHSU Knight Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.